<DOC>
	<DOCNO>NCT03028480</DOCNO>
	<brief_summary>This study special drug use investigation program NUCALA ( brand name Mepolizumab ) administer subcutaneously ( SC ) . In study information regard safety effectiveness long term use NUCALA subcutaneous injection collect Asthma subject daily clinical practice . The observation period per subject 52 week initiation NUCALA treatment follow-up investigation 2 year observation period . NUCALA register trademark GlaxoSmithKline [ GSK ] group company</brief_summary>
	<brief_title>Long Term Special Drug Use Investigation Mepolizumab</brief_title>
	<detailed_description />
	<criteria>Subjects receive NUCALA first time treatment bronchial asthma ( refractory asthma whose symptom inadequately control despite receive standard asthma medication ) No exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Exacerbation</keyword>
	<keyword>Mepolizumab</keyword>
	<keyword>NUCALA</keyword>
</DOC>